884 related articles for article (PubMed ID: 22503115)
21. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
[TBL] [Abstract][Full Text] [Related]
22. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
23. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
24. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
25. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
26. Staging of alpha-synuclein in the olfactory bulb in a model of Parkinson's disease: cell types involved.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Mohedano-Moriano A; Fradejas N; Calvo S; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
Mov Disord; 2010 Aug; 25(11):1701-7. PubMed ID: 20574962
[TBL] [Abstract][Full Text] [Related]
27. α-Synuclein: membrane interactions and toxicity in Parkinson's disease.
Auluck PK; Caraveo G; Lindquist S
Annu Rev Cell Dev Biol; 2010; 26():211-33. PubMed ID: 20500090
[TBL] [Abstract][Full Text] [Related]
28. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
29. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
30. Autonomic involvement in Parkinson's disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers.
Cersosimo MG; Benarroch EE
J Neurol Sci; 2012 Feb; 313(1-2):57-63. PubMed ID: 22001247
[TBL] [Abstract][Full Text] [Related]
31. Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3.
Meloni G; Vašák M
Free Radic Biol Med; 2011 Jun; 50(11):1471-9. PubMed ID: 21320589
[TBL] [Abstract][Full Text] [Related]
32. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
33. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein.
Lee HJ; Khoshaghideh F; Lee S; Lee SJ
Eur J Neurosci; 2006 Dec; 24(11):3153-62. PubMed ID: 17156376
[TBL] [Abstract][Full Text] [Related]
34. Pathological roles of α-synuclein in neurological disorders.
Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
[TBL] [Abstract][Full Text] [Related]
35. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
[TBL] [Abstract][Full Text] [Related]
36. Prion-like Propagation of α-Synuclein Is Regulated by the FcγRIIB-SHP-1/2 Signaling Pathway in Neurons.
Choi YR; Cha SH; Kang SJ; Kim JB; Jou I; Park SM
Cell Rep; 2018 Jan; 22(1):136-148. PubMed ID: 29298416
[TBL] [Abstract][Full Text] [Related]
37. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
39. Synucleinopathies from bench to bedside.
Puschmann A; Bhidayasiri R; Weiner WJ
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S24-7. PubMed ID: 22166445
[TBL] [Abstract][Full Text] [Related]
40. The Interplay between Alpha-Synuclein Clearance and Spreading.
Lopes da Fonseca T; Villar-Piqué A; Outeiro TF
Biomolecules; 2015 Apr; 5(2):435-71. PubMed ID: 25874605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
